Should your breast cancer patients be taking GLP-1s?
Industry Buzz
This study suggests that GLP-1 drugs may offer protective benefits, potentially improving survival and recurrence risk in some female patients with breast cancer, whether this is related to weight control, improve[d] cardiovascular health, or other mechanisms remains to be studied.
—Bernard F. Fuemmeler, PhD, MPH, via a press release
The drugs that have transformed obesity treatment may now be forcing oncologists to rethink the relationship between metabolism and cancer.
New findings suggest that GLP-1 receptor agonists could also be linked to lower recurrence and mortality rates in patients with breast cancer, raising fresh questions about whether metabolic therapies may eventually influence survivorship outcomes.[]
Potential implications for cancer care
In a retrospective analysis of more than 840,000 patients with breast cancer, researchers found that patients with obesity or type 2 diabetes who received GLP-1 therapies experienced lower all-cause mortality and reduced recurrence risk over 10 years of follow-up compared with similar patients who did not receive the drugs.[]
Although the findings are observational, they arrive at a time of growing interest in the role that metabolic dysfunction may play in cancer progression. So, could targeting metabolic pathways become part of long-term cancer management?
“This study suggests that GLP-1 drugs may offer protective benefits, potentially improving survival and recurrence risk in some female patients with breast cancer, whether this is related to weight control, improve[d] cardiovascular health, or other mechanisms remains to be studied,” Bernard F. Fuemmeler, PhD, MPH, associate director for population sciences at VCU Massey Comprehensive Cancer Center, said in a press release.[]
Why oncologists are paying attention
The biologic rationale is difficult to ignore. Obesity and metabolic dysfunction have long been associated with poorer breast cancer outcomes, particularly in postmenopausal disease.[] Excess adiposity may contribute to tumor growth through chronic inflammation, insulin resistance, and increased estrogen production.[]
Against that backdrop, the reported association between GLP-1s and improved outcomes is drawing significant attention. Researchers observed lower recurrence rates among breast cancer survivors taking GLP-1 therapies such as tirzepatide, though the study was not designed to establish causation.[]
The implications could extend beyond weight loss alone. Some investigators hypothesize that GLP-1 signaling may directly affect tumor biology, while others believe the benefit is more likely tied to improvements in metabolic and inflammatory pathways.[]
The findings may be especially relevant for patients struggling with weight gain during endocrine therapy, an issue that can negatively affect both quality of life and treatment adherence. In that context, GLP-1 therapies could eventually offer dual benefits in survivorship care: improving metabolic health while potentially influencing long-term cancer outcomes.
Related: What docs can't afford to overlook amid the GLP-1 boomWhether GLP-1s can improve outcomes remains unclear
Despite the enthusiasm, experts caution against interpreting GLP-1s as anticancer therapies—at least for now. The analysis remains retrospective and susceptible to confounding variables, including differences in baseline health, access to care, and concurrent treatments.
Whether the observed benefit is driven primarily by weight loss, improved metabolic function, or drug-specific mechanisms remains unclear. But as evidence continues to accumulate, GLP-1 therapies are rapidly moving beyond peripheral survivorship discussions.